Cleveland, OH (PRWEB) April 09, 2013
Partnerships between industry and vendors are a positive trend for the drug discovery industry when the right companies come together, as they allow for innovation and also optimize the process to facilitate identifying the right drugs faster and more effectively. On Friday, May 10th, 2013, ChanTest will host its second User Meeting: Partnerships in Drug Discovery. The User Meeting will be held in South San Francisco, California at the Westin San Francisco Airport, 1 Old Bayshore Highway, Millbrae, CA 94030.
This complimentary event highlights the latest advances and strategies for Ion channel and GPCR screening, along with profiling for drug discovery and preclinical cardiac safety testing. “The second ChanTest User Meeting: Partnerships in Drug Discovery will bring together users and partners, present new offerings, project news and coordinate future developments,” said Chris Mathes, Ph.D., Chief Commercial Officer.
This year’s keynote speaker will be Dr. Philip Sager, Chair of the Scientific Committee, Cardiac Safety Research Consortium. He will speak on “Preclinical and Clinical Development”. The event is co-sponsored by Axion Biosystems, Cellular Dynamics International, ACEA Biosciences, Sophion and Molecular Devices.
Friday, May 10, 2013
2nd ChanTest User Meeting: Partnerships in Drug Discovery
Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
About ChanTest® – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.
ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.
Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.
Visit http://www.chantest.com to learn more about what we do.